Tackling Chronic Disease With Credibility, Not Hysteria

Commentary

America faces a growing crisis in chronic disease. Obesity affects 41.9 percent of adults and 20.6 percent of adolescents, fueling diabetes, hypertension, and heart conditions that cost our healthcare system over $400 billion annually. These illnesses cut life expectancy, strain families, and burden communities, demanding serious, evidence-based solutions and a public conversation rooted in facts, not fear.

Yet, the Make America Healthy Again (MAHA) movement, which could lead this charge, risks losing its way when some aligned voices amplify misinformed claims about medical treatments. Misrepresentations, like exaggerated fears about weight loss drugs being misused in children, distract from real progress and erode trust in science.

Let’s set the record straight: anti-obesity medications, such as GLP-1 therapies like semaglutide, are not approved for children under 12. For adolescents with severe, treatment-resistant obesity—a condition that can slash decades off life—drugs like Wegovy are prescribed only under strict medical oversight. A 2022 New England Journal of Medicine study confirmed their safety and efficacy for teens, with careful monitoring. These are not casual prescriptions but evidence-based decisions by physicians and families, grounded in clinical trials, not pharmaceutical marketing.

Research into pediatric uses of these drugs is rigorous, with ongoing trials addressing safety, growth, and long-term outcomes. This is how responsible medicine works: through data, peer review, and transparency—not sensationalized narratives. Misinformation about medical care fuels public distrust, distorts policy debates, and weakens MAHA’s credibility as a platform for reform.

Valid questions deserve debate: How do we ensure access to therapies, especially for underserved communities? Can we lower treatment costs, which often exceed $1,000 monthly? Are we investing enough in prevention through nutrition, physical activity, and mental health support, given stress and anxiety’s role in obesity? These are the conversations MAHA was built to lead. But when complex issues are reduced to inflammatory soundbites, we lose sight of solutions. Outrage may spark headlines, but it doesn’t help families navigating these challenges.

Public skepticism about healthcare isn’t baseless—high drug prices and past industry missteps fuel mistrust. Yet, misrepresenting medical care only deepens confusion. MAHA could channel this energy into real reform, like advocating healthier school nutrition programs or community health initiatives to promote fitness and mental wellness. These efforts could address chronic disease at its roots, reducing reliance on costly treatments.

MAHA’s mission—to spark an honest conversation about health—is too vital to be derailed by oversimplification. The public deserves better than clickbait. Solving obesity, diabetes, and other chronic illnesses requires public figures who inform, not inflame. The real enemies aren’t pediatricians or researchers but misinformation, stigma, and a crisis that continues to shorten lives.

We don’t need to agree on every solution, but we must ground this fight in science. Tackling chronic disease will take clarity, compassion, and collaboration—not soundbites. MAHA can lead by amplifying credible voices and fostering policies that prevent illness, support families, and ensure all Americans have a fair shot at health. Let’s move the needle together.

Views expressed in this article are the opinions of the author and do not necessarily reflect the views of The Epoch Times.